Earnings Report for November 11, 2025: ALC, OKLO, DOX, CAE, ORLA, SMWB, HYLN, LPTH, STXS, PAL, EPM, QUIK Released After Market Hours
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy STXS?
Source: NASDAQ.COM
Earnings Reports Overview: Several companies, including Alcon Inc., Oklo Inc., and Amdocs Limited, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Alcon Inc. Performance: Alcon Inc. is expected to report earnings per share (EPS) of $0.77, a 4.94% decrease from the previous year, and has a Price to Earnings (P/E) ratio of 24.07, indicating potential growth compared to industry competitors.
Oklo Inc. and Other Companies: Oklo Inc. anticipates a significant EPS drop to -$0.13, while other companies like CAE Inc. and Similarweb Ltd. also project declines in EPS compared to the same quarter last year.
Mixed Results Across Sectors: Companies such as Proficient Auto Logistics and Evolution Petroleum Corporation are expected to show minimal changes or declines in EPS, reflecting a diverse range of financial health across different sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STXS
Wall Street analysts forecast STXS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.030
Low
4.00
Averages
4.20
High
5.00
Current: 2.030
Low
4.00
Averages
4.20
High
5.00
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stereotaxis to Acquire Robocath for Up to $45 Million
- Acquisition Overview: US medical technology company Stereotaxis has agreed to acquire smart robotic solutions developer Robocath for up to $45 million, aiming to enhance its market position by expanding its platform to support a wider range of endovascular procedures.
- Revenue Projections: Robocath is expected to contribute approximately $2 million in annual revenue in the first post-acquisition year, with the transaction anticipated to break even in the third year, providing positive support for Stereotaxis's financial performance.
- Technology Integration: The deal will combine Stereotaxis's magnetic navigation technology with Robocath's mechanical robotic system, delivering a synergistic solution to enhance the efficiency of endovascular surgeries, while Stereotaxis plans to fast-track the development of Robocath's next-generation system, aiming for regulatory clearance in the US and Europe within two years.
- Strategic Significance: Stereotaxis Chairman and CEO David Fischel stated that acquiring Robocath represents a highly strategic addition, not only enhancing the company's technological leadership but also opening new avenues for growth and supporting the pursuit of other strategic opportunities.
See More
Stereotaxis Acquires Robocath to Enhance Surgical Robotics for Cardiology
- Acquisition Agreement: Stereotaxis has signed a definitive agreement to acquire French company Robocath for $20 million upfront, with potential contingent payments of up to $25 million based on regulatory and commercial milestones, reflecting the company's commitment to expanding its presence in the surgical robotics market.
- Technological Integration: The acquisition combines Stereotaxis' magnetic navigation system with Robocath's mechanical robotic platform, creating a fully integrated solution aimed at improving precision and efficiency in endovascular surgery, thereby reinforcing its market leadership.
- Revenue Expectations: Stereotaxis estimates that Robocath will contribute approximately $2 million in revenue in the first year post-acquisition, with breakeven expected by year three, supported by commercial synergies between the two companies.
- Market Performance Review: Stereotaxis shares have traded between $1.69 and $3.59 over the past year, closing at $2.03, up 5.73% from the previous day, indicating positive market sentiment towards its acquisition strategy.
See More
Stereotaxis to Acquire France's Robocath for $20M
- Acquisition Overview: Stereotaxis has agreed to acquire France-based Robocath for an upfront payment of $20 million, with additional contingent payments of up to $25 million tied to regulatory and commercial milestones, expected to close in mid-2026, significantly enhancing Stereotaxis' market position in endovascular procedures.
- Technological Integration: Robocath's flagship R-One+ system is currently the only commercially available robotic solution for percutaneous coronary interventions in Europe, and Stereotaxis plans to accelerate the development of Robocath's next-generation system and pursue regulatory submissions in the U.S. and Europe within the next two years, thereby expanding its product line.
- Financial Expectations: Robocath is estimated to contribute approximately $2 million in annual revenue during the first year post-acquisition, with expectations to break even by the third year post-acquisition, supported by commercial and operational synergies, further enhancing Stereotaxis' financial performance.
- Market Outlook: This acquisition not only strengthens Stereotaxis' technological capabilities but also lays the groundwork for future product innovation and manufacturing expansion, targeting over $40 million in annual revenue by 2026, demonstrating the company's strong confidence in the medical robotics market.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Milestone: Stereotaxis Inc.'s Synchrony system has received 510(k) clearance from the U.S. FDA, marking a significant milestone in modernizing interventional catheter laboratories, which is expected to enhance the company's market share in surgical robotics.
- Enhanced System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates multiple systems into one intuitive platform, significantly improving visualization and operational efficiency in interventional procedures through custom layouts and streamlined workflows.
- Cloud Connectivity Benefits: The integration with the SynX cloud application enables secure remote collaboration among physicians during operations, enhancing workflow efficiency and patient care quality, thus meeting the high technological demands of modern healthcare.
- Foundation for Future Innovations: Stereotaxis reiterated its guidance of generating over $3 million in revenue this year from Synchrony systems placed independently of robotic systems, emphasizing that this technology will lay the groundwork for future AI applications and remote robotic procedures, driving industry advancement.
See More
Stereotaxis Secures FDA 510(k) Clearance for Synchrony System
- FDA Clearance: Stereotaxis announced that its Synchrony system has received FDA 510(k) clearance, marking a significant advancement in the digitization and modernization of interventional cath labs, which is expected to enhance market competitiveness.
- System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates the viewing and control of all disparate systems in the lab, improving operational efficiency and enhancing the physician's working experience.
- Cloud Application: The system is compatible with the SynX cloud-based application, ensuring compliance with HIPAA and GDPR standards, providing secure remote connectivity, collaboration, recording, and monitoring capabilities, which further enhances operational flexibility in the lab.
- Revenue Outlook: Stereotaxis reiterated its revenue guidance for Synchrony systems, expecting to achieve over $3 million in revenue in the current year, independent of robotic system sales, demonstrating its market potential.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Approval: Stereotaxis has received 510(k) clearance from the U.S. FDA for its Synchrony™ system, marking a significant technological advancement in minimally invasive endovascular interventions, which is expected to enhance the company's market share in surgical digital transformation.
- Technological Innovation: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates all lab systems, enhancing the procedural experience and streamlining workflows, which is anticipated to significantly improve operational efficiency for physicians and patient outcomes.
- Future Development: The integration of Synchrony with the SynX™ cloud application offers secure remote connectivity and collaboration capabilities, supporting the introduction of future technologies that enhance clinical insights and automation, potentially creating new revenue streams for the company.
- Market Outlook: Stereotaxis reiterates its guidance of over $3 million in revenue from Synchrony systems this year, reflecting the company's confidence in future growth, particularly in increasingly complex electrophysiology lab environments where the value of technology is becoming more pronounced.
See More
Stereotaxis to Acquire Robocath for Up to $45 Million
- Acquisition Overview: US medical technology company Stereotaxis has agreed to acquire smart robotic solutions developer Robocath for up to $45 million, aiming to enhance its market position by expanding its platform to support a wider range of endovascular procedures.
- Revenue Projections: Robocath is expected to contribute approximately $2 million in annual revenue in the first post-acquisition year, with the transaction anticipated to break even in the third year, providing positive support for Stereotaxis's financial performance.
- Technology Integration: The deal will combine Stereotaxis's magnetic navigation technology with Robocath's mechanical robotic system, delivering a synergistic solution to enhance the efficiency of endovascular surgeries, while Stereotaxis plans to fast-track the development of Robocath's next-generation system, aiming for regulatory clearance in the US and Europe within two years.
- Strategic Significance: Stereotaxis Chairman and CEO David Fischel stated that acquiring Robocath represents a highly strategic addition, not only enhancing the company's technological leadership but also opening new avenues for growth and supporting the pursuit of other strategic opportunities.
See More
Stereotaxis Acquires Robocath to Enhance Surgical Robotics for Cardiology
- Acquisition Agreement: Stereotaxis has signed a definitive agreement to acquire French company Robocath for $20 million upfront, with potential contingent payments of up to $25 million based on regulatory and commercial milestones, reflecting the company's commitment to expanding its presence in the surgical robotics market.
- Technological Integration: The acquisition combines Stereotaxis' magnetic navigation system with Robocath's mechanical robotic platform, creating a fully integrated solution aimed at improving precision and efficiency in endovascular surgery, thereby reinforcing its market leadership.
- Revenue Expectations: Stereotaxis estimates that Robocath will contribute approximately $2 million in revenue in the first year post-acquisition, with breakeven expected by year three, supported by commercial synergies between the two companies.
- Market Performance Review: Stereotaxis shares have traded between $1.69 and $3.59 over the past year, closing at $2.03, up 5.73% from the previous day, indicating positive market sentiment towards its acquisition strategy.
See More
Stereotaxis to Acquire France's Robocath for $20M
- Acquisition Overview: Stereotaxis has agreed to acquire France-based Robocath for an upfront payment of $20 million, with additional contingent payments of up to $25 million tied to regulatory and commercial milestones, expected to close in mid-2026, significantly enhancing Stereotaxis' market position in endovascular procedures.
- Technological Integration: Robocath's flagship R-One+ system is currently the only commercially available robotic solution for percutaneous coronary interventions in Europe, and Stereotaxis plans to accelerate the development of Robocath's next-generation system and pursue regulatory submissions in the U.S. and Europe within the next two years, thereby expanding its product line.
- Financial Expectations: Robocath is estimated to contribute approximately $2 million in annual revenue during the first year post-acquisition, with expectations to break even by the third year post-acquisition, supported by commercial and operational synergies, further enhancing Stereotaxis' financial performance.
- Market Outlook: This acquisition not only strengthens Stereotaxis' technological capabilities but also lays the groundwork for future product innovation and manufacturing expansion, targeting over $40 million in annual revenue by 2026, demonstrating the company's strong confidence in the medical robotics market.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Milestone: Stereotaxis Inc.'s Synchrony system has received 510(k) clearance from the U.S. FDA, marking a significant milestone in modernizing interventional catheter laboratories, which is expected to enhance the company's market share in surgical robotics.
- Enhanced System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates multiple systems into one intuitive platform, significantly improving visualization and operational efficiency in interventional procedures through custom layouts and streamlined workflows.
- Cloud Connectivity Benefits: The integration with the SynX cloud application enables secure remote collaboration among physicians during operations, enhancing workflow efficiency and patient care quality, thus meeting the high technological demands of modern healthcare.
- Foundation for Future Innovations: Stereotaxis reiterated its guidance of generating over $3 million in revenue this year from Synchrony systems placed independently of robotic systems, emphasizing that this technology will lay the groundwork for future AI applications and remote robotic procedures, driving industry advancement.
See More
Stereotaxis Secures FDA 510(k) Clearance for Synchrony System
- FDA Clearance: Stereotaxis announced that its Synchrony system has received FDA 510(k) clearance, marking a significant advancement in the digitization and modernization of interventional cath labs, which is expected to enhance market competitiveness.
- System Features: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates the viewing and control of all disparate systems in the lab, improving operational efficiency and enhancing the physician's working experience.
- Cloud Application: The system is compatible with the SynX cloud-based application, ensuring compliance with HIPAA and GDPR standards, providing secure remote connectivity, collaboration, recording, and monitoring capabilities, which further enhances operational flexibility in the lab.
- Revenue Outlook: Stereotaxis reiterated its revenue guidance for Synchrony systems, expecting to achieve over $3 million in revenue in the current year, independent of robotic system sales, demonstrating its market potential.
See More
Stereotaxis Receives FDA Clearance for Synchrony System
- FDA Approval: Stereotaxis has received 510(k) clearance from the U.S. FDA for its Synchrony™ system, marking a significant technological advancement in minimally invasive endovascular interventions, which is expected to enhance the company's market share in surgical digital transformation.
- Technological Innovation: The Synchrony system features a 55-inch 4K ultra-high-definition display that consolidates all lab systems, enhancing the procedural experience and streamlining workflows, which is anticipated to significantly improve operational efficiency for physicians and patient outcomes.
- Future Development: The integration of Synchrony with the SynX™ cloud application offers secure remote connectivity and collaboration capabilities, supporting the introduction of future technologies that enhance clinical insights and automation, potentially creating new revenue streams for the company.
- Market Outlook: Stereotaxis reiterates its guidance of over $3 million in revenue from Synchrony systems this year, reflecting the company's confidence in future growth, particularly in increasingly complex electrophysiology lab environments where the value of technology is becoming more pronounced.
See More
